RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
Bayhill focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance. The company was dissolved in 2012.
Bayhill Therapeutics
San Mateo, CA
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.